Updated Jul 16, 2026
Corvese Brian has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.

Brian Corvese is an individual identified in SEC filings dated 2026-04-28 in connection with Agenus Inc. and MiNK Therapeutics, Inc. The filings indicate his status as an insider (such as a director or officer) at these companies, but public sources do not clearly disclose his exact title or responsibilities. Agenus is a biotechnology company focused on cancer immunotherapies, and MiNK Therapeutics specializes in NK cell-based therapies. Beyond regulatory disclosures, there is limited publicly verifiable biographical information about Mr. Corvese.
| Role | Insider |
|---|---|
| Notability | 15/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-02 | INKT | MiNK Therapeutics, Inc. | A — Grant or award | 1.4K | $12.38 | $18K |
| 2026-06-02 | INKT | MiNK Therapeutics, Inc. | A — Grant or award | 1.6K | $10.90 | $18K |
| 2025-12-03 | INKT | MiNK Therapeutics, Inc. | A — Grant or award | 1.6K | $11.09 | $18K |
| 2025-09-02 | INKT | MiNK Therapeutics, Inc. | A — Grant or award | 1.3K | $13.86 | $18K |
| 2024-12-03 | INKT | MiNK Therapeutics, Inc. | A — Grant or award | 24.4K | $0.73 | $18K |
Brian Corvese is an individual identified in SEC filings dated 2026-04-28 in connection with Agenus Inc. and MiNK Therapeutics, Inc. The filings indicate his status as an insider (such as a director or officer) at these companies, but public sources do not clearly disclose his exact title or responsibilities. Agenus is a biotechnology company focused on cancer immunotherapies, …
2 primary Form 4 filings in the last 90 days, covering 2 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Corvese Brian profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.